Policy | August 06, 2021
Govt augments PSEs and Bharat Biotech to ramp up Covaxin production
CDSCO to fast-track trials and approval for COVID19 vaccine
CDSCO to fast-track trials and approval for COVID19 vaccine
WHO prequalification enables the procurement of ROTAVAC 5D by UN agencies namely UNICEF and PAHO
It is expected that the drug substance would be available from August 2021 which will be supplied back to Bharat Biotech for producing COVAXIN
We focused on developing the product last year but now our focus is on ramping up our manufacturing capacity
“One Earth, One Health” vision can become a reality only with active global collaboration where countries don’t think of only themselves, but of collective global outcomes
The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics
Phase-III trials were conducted for safety, and immunogenicity in around 3,100 subjects, in 14 trial sites across India (supported by BIRAC)
The Coalition for Epidemic Preparedness Innovations (CEPI) has recently partnered with the consortium of India-based Bharat Biotech, University of Sydney and ExcellGene to develop “variantproof” COVID-19 vaccine.
Ours is a story of India’s resilient public health system and of everyone working together as team India to battle the pandemic
The approval by the DCGI comes following recommendations by the Subject Expert Committee (SEC) on Covid-19 of the Central Drugs Standard Control Organisation(CDSCO)
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)